Bumbu is back with an all-new video starring their new spokesman DJ Khaled.
The video sees DJ Khaled in a private yoga session with an instructor encouraging him to be the G.O.A.T., or “The Greatest of All Time.” As she prompts Khaled to “bring out the inner G.O.A.T.,” live goats fill the studio - one even posing atop Khaled’s shoulders! As funny as it looks, this “goat yoga” practice has become an increasingly popular trend in recent years.
Bumbu has been embracing goats as a tie-in with their tagline “The Greatest of All Time,” so goat yoga was the perfect marriage of their campaign with DJ Khaled’s permanent positivity.
DJ Khaled’s yoga mantra, “I am always progressing, I am always becoming,” means there’s always room for growth and development. “Always strive to be the G.O.A.T. in everything you do,” says Khaled. “Be the G.O.A.T. friend, the G.O.A.T. business partner, the G.O.A.T. team member, the G.O.A.T. to your significant other.”
Khaled’s Bumbu spot comes on the heels of the brand’s first G.O.A.T. video, starring Lil Wayne. It’s nice to know DJ Khaled and Lil Wayne share a love of both Bumbu and--of course--being the G.O.A.T.!
Click HERE to watch DJ Khaled doing goat yoga!
Click HERE to download the video!
About Bumbu
Bumbu is a premium, all-natural craft rum distilled, aged, and bottled in Barbados at a beachside distillery opened in 1893. The rum is an authentic recreation of a Caribbean legend, made using a 400-year old recipe for the original “Bumbu” made by sailors of the 16th and 17th century West Indies. Using sugarcane sourced from eight different countries, distilled and blended with Barbados’ naturally coral-filtered water, and aged in once-used oak bourbon barrels, Bumbu is a rum of unrivaled complexity and smoothness, and has been awarded five gold medals - including two “Best in Category” honors - in two years at the Los Angeles International Spirits Competition.
About Sovereign Brands
Sovereign Brands is a family-owned, international wine & spirits company headquartered in New York. The company is owned and operated by the Berish family and partners with first-class producers from the world's most iconic wine and spirit regions to develop superior brands. Sovereign has a portfolio of successful brands including Luc Belaire, a smash-hit line of French sparkling wines, which has earned global acclaim for its exquisite taste and striking packages, and is available in more than 100 countries around the world. The company’s portfolio also includes Bumbu, a craft rum brand from Barbados that ranks among the world’s most critically acclaimed rums, Cloud Chaser, a classic French Côtes de Provence Rosé, and Skeleton Vineyards, a range of accessible wines from Argentina and Austria.
World Fitness Expo educates and inspires with over 300 cutting-edge sessions
World famous conference and trade show presents invigorating fitness classes and high-level educational seminars
August 8-12 in Toronto
TORONTO, ON — This month, fitness enthusiasts, industry professionals and newcomers alike are getting a sneak peek at the latest trends in health and wellness at
canfitpro World Fitness Expo. Attendees will get the opportunity to customize their experiences with a selection of over 300 innovative fitness, wellness and nutrition sessions, presented by over 200 industry experts. Now in its milestone 25
th year, the canfitpro World Fitness Expo returns to the Metro Toronto Convention Centre August 8-12 to entertain thousands and inspire the next generation of fitness lovers.
Both experts in the field and those looking to strengthen their knowledge and routine will enjoy a wide range of workout sessions and training seminars led by exclusive celebrity talent including Jillian Michaels, Derek Hough, Tae Bo’s Billy Blanks and dancing bodybuilders, The Brutez. With hundreds of sessions from Zumba, cycling and interval training to kickboxing and ballet, there’s something for every fitness level and interest.
Calisthenics
A popular workout gaining recognition for its intense results and minimal equipment, calisthenics are predominantly bodyweight exercises intended to increase strength and flexibility through movements that use the body for resistance. Moving freely without any restrictions, calisthenics offers muscular and aerobic conditioning that improves psychomotor skills such as balance, agility and coordination. This year’s canfitpro World Fitness Expo features a calisthenics competition led by Quebec-based, Calistation.
Hot Booty Ballet
This booty-toning fitness trend is based on traditional ballet conditioning exercises that will shape, sculpt and stretch the glute muscles. Meant to increase your metabolism and burn fat to achieve optimal results, Hot Booty Ballet stands out thanks to the use of Hot Booty Bands for added resistance training. Returning to canfitpro World Fitness Expo this year, attendees can enjoy routines choreographed to match the lyrics and musicality of each song, taking this class to the next level.
YogaFit®
Founded in 1994, YogaFit is the largest yoga school in North America. Best known for its safe and inclusive approach, it focuses on the mind and body, offering classes on the safety and best practices for every individual. This year, YogaFit presents multiple sessions, including Fit and Focused Kids, a class showing how to bond with children through movement, breath, and imagery practices; and Injury Prevention and Awareness, where attendees can learn how yoga reduces the risk of injury and promotes rehabilitation and wellness.
As the largest industry conference and trade show, canfitpro World Fitness Expo aims to deliver exceptional health and fitness learning experiences and provide attendees with the skills and tools they need to take their routines beyond the gym and the classroom. Discover the full list of sessions here and the exhibitor list here. Attendees can register for sessions and purchase tickets to expo hall online at worldfitnessexpo.com.
Website: www.worldfitnessexpo.com
Twitter: @canfitpro
Instagram: @canfitpro
Facebook: @canfitpro
Hashtag: #canfitpro #worldfitnessexpo
About canfitpro
canfitpro is the largest provider of education in the Canadian fitness industry. Founded in 1993, canfitpro delivers accessible, quality education, certifications, events and membership services. canfitpro's over 24,000 members include some of the world's finest fitness professionals, health club operators, industry suppliers, and fitness consumers.
MYM Partners With Award Winning Dutch Passion for the Production and Distribution of Cannabis Seeds in Australia
VANCOUVER, Aug. 1, 2018 /CNW/ - MYM Nutraceuticals Inc., (CSE: MYM) (CSE: MYM.CN) (OTC: MYMMF) ("MYM") is pleased to announce it has entered into a two-year agreement with Amsterdam-based Dutch Passion for the production and distribution of Dutch Passion branded products and seed genetics in Australia.
Established in 1987 Dutch Passion is the second oldest European Cannabis seed company and for over 30 years has been a leading innovator of seed genetics. Dutch Passion has developed its own proprietary genetics and owns a seed collection of international cannabis genetics dating back to the 1970s. Since Dutch Passion was established in 1987, the company has won more than 50 Cannabis Cups for its high-THC, easy-to-grow varieties. Dutch Passion also invented feminized cannabis seeds in the 1990s and, more recently, helped pioneer the success of high-THC auto-flowering cannabis seeds.
"We are thrilled to be working with Dutch Passion in Australia. With over 30 years-experience in the development and distribution of cannabis seeds, they are considered to be world leaders," said Rob Gietl, CEO of MYM. "As legal production of cannabis has been rapidly increasing worldwide, so has the demand for seed genetics. The Dutch Passion portfolio of seeds will prove to be a very valuable asset to the shareholders of MYM."
Eric Siereveld, CEO of Dutch Passion Seed Company commented, "There were a lot of options when we were considering working with producers in Australia. We chose to partner with MYM because of their strong network and organization in the global cannabis industry. We are confident that MYM has the best environment to maximize the potential of the genetic products we offer."
Dutch Passion agreed to give MYM exclusive rights in Australia to produce and distribute under the Dutch Passion brand, all products that Dutch Passion sells currently and may sell in the future, including: clones, flowers, pre-rolled joints and other cannabis products. Australia is poised to be one of the worlds leading exporters of Cannabis products due to its favorable growing environment and low production costs. Dutch Passion also agreed to give MYM non-exclusive rights in Australia to produce and/or distribute cannabis seeds under the Dutch Passion brand.
MYM agreed to make Dutch Passion its flagship brand of cannabis seeds for sale in Australia and Dutch Passion agreed to list MYM as an official distributor of products in Australia.
About Dutch Passion
Dutch Passion is a Dutch company with over 30 years' experience in the development and distribution of cannabis seeds. Dutch Passion is focused on producing high quality, high-THC cannabis genetics and on providing attentive customer service through its experienced customer service team. Dutch Passion's diverse seed collection of international cannabis genetics dates back to the 1970s, with all varieties having passed strict tests designed to ensure ease of growth, heavy yields and high-quality results. In the 1990s, Dutch Passion invented feminized cannabis seeds and, more recently, helped to pioneer the success of high-THC auto-flowering cannabis seeds. http://www.dutch-passion.com
About MYM Nutraceuticals Inc.
MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end medicinal cannabis supplements and topical products. MYM is a shareholder in two production projects in Quebec that when completed are anticipated to have over 1.5 million square feet of production space. MYM is also a shareholder in two international cannabis production projects in Australia and Colombia. In New South Wales, Australia, the "Northern Rivers Project" is expected to have 1.2 million square feet of cannabis production space. In Medellin, Colombia, MYM and Colombia Organica have partnered and are planning to build a cannabis production facility in the region. Colombia Organica currently holds a seed to sale license for low THC cannabis which permits the company to grow, produce and create cannabis derivatives to be commercialized and / or exported. Colombia Organica is in the licensing process for the cultivation and production of high THC cannabis extracts. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE: MYM) (OTC: MYMMF) (FRA: 0MY) (DEU: 0MY) (MUN: 0MY) (STU: 0MY).
This release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws, including statements regarding the production and distribution of Dutch Passion branded products in Australia, the anticipated access to and commercial value of Dutch Passion's list of seeds and cannabis products, the anticipated combined production space of 1.5 million square feet for the two production projects in Quebec, the anticipated 1.2 million square feet of production space in the Northern Rivers Project, and the building of a cannabis production facility in Colombia. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends," "anticipates," "it is expected," or variations of such words and phrases, or statements that certain actions, events or results "may," "could," "should," or "would" occur. Forward-looking statements are based on certain material assumptions and analyses made by the Company and the opinions and estimates of management as of the date of this press release, including the assumption that the terms and conditions of the agreements with Dutch Passion will be carried out and satisfied as anticipated, that MYM will have access to Dutch Passion's list of seeds and cannabis products and that it will be a commercially valuable asset, that the Northern Rivers Project will be completed as planned, including the construction and operation of 1.2 million square feet of production space, that MYM's projects in Quebec will be completed as planned, with 1.5 million square feet of greenhouse space, and that the cannabis production facility will be successfully built near Medellin, Colombia as anticipated by MYM. Although the Company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements. Such risk factors may include, among others, the risk that the terms and conditions of the agreements with Dutch Passion will not be carried out or satisfied as anticipated, or at all, that MYM will not have access to Dutch Passion's list of seeds and cannabis products due to unforeseen complications or, if it does, that such list of seeds and cannabis products will not be commercially valuable, MYM's Quebec projects will not be successfully built as planned, the Northern Rivers Project will not be successfully built as planned, the cannabis production facility will not be successfully built as planned, and the other risks and uncertainties applicable to the Company's business as set forth in the Company's management discussion and analysis and annual information form and the Company's other disclosure available under the Company's profile at http://www.sedar.com. There can be no assurance that the transactions contemplated in this news release will complete. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that is incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
Investor Relations
SOURCE MYM Nutraceuticals Inc.
Optina Diagnostics Looks to Advance Biomarker Discovery Through Collaboration with Imagia
MONTREAL, Aug. 1, 2018 /CNW/ - Optina Diagnostics, a leading-edge company with a vision to revolutionize the way that Alzheimer's is diagnosed, announces today a collaborative agreement with Imagia, a Healthcare AI company whose mission is to personalize health care. Together they will be focusing on the development of retinal biomarkers for Alzheimer's disease by leveraging spectral retinal images combined with deep learning architectures to predict patient outcomes and detect disease specific markers.
The solution towards a cure for Alzheimer's begins with the early detection of the disease in order to treat it before irreversible damage occurs. Currently, the diagnosis of Alzheimer's relies on a variety of neurobehavioral tests that are subjective, as well as PET scans that are both expensive and inconvenient.
"The opportunity to work closely with the experts at Imagia Cybernectics on the discovery of spectral biomarkers for early stage, low cost, non-invasive diagnostics of Alzheimer's disease is extremely motivating," said David Lapointe, CEO at Optina Diagnostics.
"By combining our data rich images from a large number of very narrowband wavelengths with the deep learning pipelines developed by Imagia Cybernetics, we believe we can accelerate the delivery of novel biomarkers and predict patient outcomes".
"This collaboration aligns with Imagia's initiative in preventative health. Leveraging our deep radiomics platform, we aim at discovering actionable imaging biomarkers from Optina's unique spectral retinal imaging, to improve Alzheimer's patient management." said Florent Chandelier CTO at Imagia.
About Optina Diagnostics
Optina Diagnostics is a Montreal based company focused on the development of technology for the early detection of disease through hyperspectral imaging of the eye. With a first application in the early diagnosis of Alzheimer's, Optina brings a radiomics approach to biomarker detection. optinadx.com
About Imagia
Imagia Cybernetics is a Healthcare AI company, translating technology innovations into impactful patient care and experience. Our team of AI experts and clinical practitioners have purpose-built Evidens, a collaboration ecosystem that powers discovery and clinical adoption at scale — federating patient data across institutions and uniting creative minds in AI & healthcare. Together with leading pharma, imaging and interventional medical device companies, we are propelling healthcare AI products to reveal the full picture of personalized healthcare. Imagia.com
SOURCE Optina Diagnostics
How Music Has The Power
To Heal What Ails You
Studies have shown music’s almost magical impact on healing and music is being used in a variety of new ways, such as teaching stroke patients how to walk and helping premature babies gain weight.
“Music treats the soul, and If you treat your soul the body will ultimately positively react,” says D. Kenny Davin Fine MD, a gastroenterologist who is also creator of Oro-Intestinal Fitness Products (www.finerhealth.com). “Music is under appreciated as a healing source that can be just as powerful a prescription as drugs.”
Fine, a musician himself who recently recorded a “Rockspirational” double music album, has used his scientific and medical expertise to pioneer new paradigms to diagnose and treat a variety of illnesses and conditions. But he says music can be therapeutic as well.
“Music can be an integral part of creating a unique prescription of health, happiness and hope,” says Fine, who has also created the FinerHealth, FinerLife Travelling Musical Medicine Show which he will soon take on the road to live events.
Fine offers these recommendations for people who are having medical issues and want to incorporate music as a healing therapy:
- Sing to yourself even if it is just in the car or the shower. Research has shown that music not only engages the auditory system but many other parts of your brain as well, including areas responsible for movement, language, attention, memory, and emotion. The impact can be felt regardless of if a person is listening to music, playing an instrument or singing.
- Take off the headphones. Headphones cranked up too loud cause hearing loss. Listen more to soothing music that relaxes you at lower volumes. If you can’t give up the headphones, a good rule of thumb is to not turn the volume up so loud that you can’t hear other sounds around you.
- Learn to play an instrument. This not only enhances your music appreciation, but will encourage you to listen to more. Learning to play a musical instrument also is one of the best exercises for your brain.
“Music is an important part of our lives, but for people who have health issues, it could play an even more important role if they only utilized it,” Fine says. “I believe we are only beginning to scratch the surface when it comes to the healing power of music. I think in the coming years we will have more hard evidence of its potential. I even predict that in the future people will choose their health practitioner not only for their specialty, and personality but in what area of creativity they dwell.”
About Kenny Davin Fine MD
Kenny Davin Fine MD, creator of Oro-Intestinal Fitness Products (www.finerhealth.com), is a gastroenterologist who has held staff positions at both Baylor University Medical Center and the University of Texas-Southwestern Medical School. His medical research has appeared in prestigious medical journals including The New England Journal of Medicine, Gastroenterology, The Journal of Clinical Investigation, and The American Journal of Gastroenterology. He has been professionally involved in patient care, medical research, teaching, directing clinical laboratories, nutritional pioneering and original health product and unique organic health food product development for almost 30 years. Fine is also a highly regarded singer-songwriter, guitar and harmonica player, and recording artist with 11 album releases to date. He has worked in the recording studio with Grammy and Oscar-winning producers, including Michael Lloyd, Niko Bolas, and John Hampton. He proclaims he is the world’s only Physician-Musician on a Mission!
Crooked Teeth, Extra Pounds And Other Surprising
Culprits Wrecking Your Sleep
There’s nothing like waking refreshed after a good night’s sleep.
For too many people, though, it doesn’t happen enough – if at all.
“No one really knows why we sleep, but we do know that sleep is essential for survival and that 70 million Americans suffer from a sleep problem,” says Dr. Daniel Klauer, DDS, author of Achieve Your Victory: Solutions for TMD and Sleep Apnea (www.drdanielklauer.com).
The inability to log enough hours of shuteye each night is more than just an annoyance. Conditions that prevent or affect sleep can lead to a cascade of negative health consequences, says Klauer, whose dental practice makes sleep breathing disorders a focus.
“A sleep breathing disorder can cause someone to stop breathing, either partially or completely, when they’re sleeping,” Klauer says. “That can result in daytime sleepiness or fatigue that often reduces quality of life and inability to function throughout the day.”
The most common such disorder is obstructive sleep apnea, which can lead to other health problems, including chronic diseases, such as diabetes, and even death. He says he see more men who have sleep symptoms than women.
A number of factors, some less surprising than others, can contribute to obstructive sleep apnea, Klauer says. Those include:
- Crooked teeth. If you have crooked teeth, that’s an indication your tongue doesn’t have the space it needs inside the mouth. “When there’s not enough room, the tongue can obstruct the airway,” Klauer says. Of course, even people with straight teeth can have obstructive breathing, he says. It’s just less likely for them.
- Improper jaw development. If the maxilla (upper jawbone) and mandible (lower jaw) aren’t fully developed forward and wide, the dimensions of your airway will be reduced.
- Swollen tonsils and adenoids. Tonsils and adenoids are lymphatic tissue that rest in the back of the throat and nasal cavity. If they become swollen, they take up space within the airway and cause breathing problems.
- Weight issues. Obesity causes increased fat deposition in the soft-tissue passages of the airway and decreased muscle tone. That makes it more difficult to breathe and increases the chances of an airway collapse at night, Klauer says.
Once you’ve determined what problem is causing your obstructive sleep apnea, the next step is to look for solutions. Klauer says the first line of treatment for patients with mild to moderate symptoms is a Continuous Positive Airway Pressure (CPAP) machine or Oral Appliance Therapy.
CPAP Therapy requires wearing a mask on your face at night that blows air through your nose to keep your airway from collapsing at night.
Oral Appliance Therapy requires wearing a customized oral appliance. This appliance serves to physiologically prevent the collapse of your airway by stabilizing your lower jaw, tongue, and soft palate.
If these efforts don’t work, surgical options may be necessary, Klauer says. Regardless, it’s important to address the issue, not only because of the health concerns, but also because of the importance of rest.
“The quality of sleep ultimately determines the quality of life,” Klauer says. “Sleep gives the body a chance to rest, recover and rejuvenate. It is the body’s way of filling the tank back up with gas.”
About Dr. Daniel Klauer, DDS
Dr. Daniel Klauer, DDS, is author of Achieve Your Victory: Solutions for TMD and Sleep Apnea (www.tmjsleepindiana.com). Since 2013, Dr. Klauer has limited his practice to treating patients with craniofacial pain, TMD, and sleep breathing disorders. Dr. Klauer is board certified with the American Board of Dental Sleep Medicine, American Board of Craniofacial Pain, and the American Board of Craniofacial Dental Sleep Medicine. He is diplomate eligible with the American Board of Orofacial Pain. He attended the University of Notre Dame and was a member of the Big East Championship Varsity Golf Team. After graduating from the University of Notre Dame, Dr. Klauer earned his doctor of dental surgery degree (DDS) from Ohio State University.
Magic in the Mix: BlenderBottle Releases Officially-Licensed Harry Potter Shaker Bottles
Lehi, Utah (July 2018) – BlenderBottle, creators of the BlenderBottle®Classic™—the original, best-selling portable mixer that revolutionized the market—adds magic to the mix with the launch of the BlenderBottle® Pro28™ Harry Potter shaker cup series.
In conjunction with the 20th anniversary of the publication of “Harry Potter and the Sorcerer’s Stone,” and perfectly timed for back-to-school excitement, the new series features officially-licensed designs of Harry Potter emblems and symbols. Included in the lineup are the Quidditch-version emblems of the houses of Gryffindor, Slytherin, Hufflepuff, and Ravenclaw—a nod to the fitness focus of the BlenderBottle brand. Additional shakers feature the Deathly Hallows symbol and Harry Potter’s iconic Bolt & Glasses.
“We’re excited to bring the world of Harry Potter to the BlenderBottle Pro28 shaker,” says Chase Morgan, Product Marketing Manager at BlenderBottle. “While the Pro28 relies on fastidiously-tested innovation and engineering to deliver rock-solid performance, its unsurpassed mixing and the ultra-smooth shakes that result can certainly seem magical.”
The beloved Harry Potter designs will accent the Pro28’s simple, clean aesthetic and customer-requested, solution-oriented features, including a 28-ounce capacity and rounded base to further enhance the patented mixing system. The shaker also incorporates the new SpoutGuard™, which enables users to easily open the flip top without touching the drinking surface. An adjustable carry loop adds hands-free convenience, and durable odor-resistant Eastman Tritan™ plastic helps keep stains and lingering flavors at bay.
The Pro28 Harry Potter series—like all BlenderBottle brand products—is made of BPA- and Phthalate-free materials and is top-rack dishwasher safe. The Harry Potter series bottles are available now for $16.99 at blenderbottle.com.
About BlenderBottle
Founded in 2000, the BlenderBottle Company is a privately held manufacturer of premium and innovative products that help simplify everyday life. The company’s patented and best-selling products have been hailed by Good Morning America, Reader’s Digest, Self, the Today Show, Men’s Fitness, and others as some of the “hottest new products” on the market.
BlenderBottle® products are available in over 90,000 retail locations worldwide, and in over 70,000 retail locations in the U.S. alone, including GNC, Vitamin Shoppe, Vitamin World, Bed Bath & Beyond, Walmart, Target, Rite Aid, Whole Foods, Amazon.com, and online at blenderbottle.com. The BlenderBottle Company is located in Lehi, Utah and markets and sells its products to retailers and resellers worldwide. All BlenderBottle® products are backed by a Customer Satisfaction Guarantee. For additional information, visit blenderbottle.com.
ProMIS Neurosciences Issues White Paper Entitled 'State of the Art at AAIC 2018'
TSX: PMN; OTCQB: ARFXF
Key conference theme: targeting toxic amyloid-beta oligomers offers renewed hope for treatment of Alzheimer's disease
TORONTO and CAMBRIDGE, MA, July 31, 2018 /CNW/ - ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced it has issued a white paper entitled 'State of the Art at AAIC 2018'.
At this year's Alzheimer's Association International Conference (AAIC), the causative role of amyloid-beta oligomers (AβO) in the development and progression of Alzheimer's disease (AD) and the importance of neutralizing AβO toxicity represented a common theme across multiple oral presentations and posters. These included details of the recent positive Phase 2 clinical results obtained with BAN2401 by Eisai/Biogen showing a dose-dependent reduction in cognitive decline compared to placebo at 12 and 18 months.
"Overall, the BAN2401 results provide strong support for targeting of AβO as a therapeutic strategy for AD. However, the encouraging results reported leave room for improvement, due to the brain swelling (ARIA) associated with plaque binding in the higher BAN2401 dose groups", stated Dr. Elliot Goldstein, ProMIS President and CEO.
"As outlined in our poster presentation at the AAIC, humanized PMN310 shows unrivaled selectivity for native toxic AβO derived from human AD brains, with no off-target binding to Aβ monomers or plaque. We believe the oligomer selectivity of PMN310 supports a potential best in class product profile compared to other therapeutic antibodies currently showing promising results in clinical trials."
Another topic of high interest centered around advancements in the use of biomarkers driven by the convergence of emerging results from several large longitudinal studies together with recent FDA guidance encouraging the use of cerebrospinal fluid (CSF) and imaging biomarkers in clinical testing.
ProMIS' clinical candidate, humanized PMN310, is on track to enter Phase 1 clinical testing in the second half of 2019 and will include biomarker assessment as an integral part of the study design.
ProMIS white paper, entitled 'State of the Art at AAIC 2018' can be found on the ProMIS website, by clicking on the link below:
https://promisneurosciences.com/presentations/aaic-white-paper-2018/
ProMIS AAIC poster presentation, entitled 'Humanized PMN310 shows enhanced therapeutic potential by binding toxic low molecular weight Aβ oligomers while avoiding ARIA-related binding to Aβ deposits in AD patient brains' can be found on the ProMIS website, by clicking on the link below:
https://promisneurosciences.com/posters/aaic-poster-2018/
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences is a development stage biotechnology company focused on discovering and developing antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN.TO, and on the OTCQB Venture Market under the symbol ARFXF.
For further information please consult the Company's website at: www.promisneurosciences.com
Follow us on Twitter
Like us on LinkedIn
Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release. This news release contains certain "forward-looking statements" within the meaning of Canadian securities legislation. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words "expects", "plans", "anticipates", believes", "intends", "estimates", "projects", "aims", "potential", "goal", "objective", "prospective", and similar expressions, or that events or conditions "will", "would", "may", "can", "could" or "should" occur. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except as required by the securities disclosure laws and regulations applicable to the Company, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors, should change.
SOURCE ProMIS Neurosciences Inc.
| Strides towards a smokeless world continue to drive positive performance for PMI but competition remains fierce, says GlobalData
Following Friday’s (27 July) announcement of Philip Morris International Inc. 2018 second quarter results, Ryan Choi, Consumer Analyst at GlobalData, a leading data and analytics company, offers his view on the company’s current progress:
“Philip Morris International Inc.’s (PMI) continued focus on their strategy to deliver a ‘smokeless world’ has led to positive second quarter results. Although competition within the heated tobacco products market is growing rapidly, PMI has a significant advantage through its well-known IQOS system and is likely to maintain it. Cigarette performance continues its downwards trajectory with overall shipment volumes in this quarter down by 1.5%.
“Despite successful strides with their leading Heated Tobacco product, IQOS, across key markets like Japan, growth has slowed down as new competitors enter the market such as Japan Tobacco with Ploom, as well as existing competition such as BAT’s Glo making positive strides as well. Forecasts remain positive for Heated Tobacco units as PMI forecasts significant growth in their in-market heated tobacco sales volume.
“Entry to the US is currently still awaiting approval from the FDA before they are able to launch IQOS into the market. On June 8th 2018, PMI submitted further research results to the FDA claiming that IQOS helps to reduce the risk of smoking related diseases and hopes that this will help them gain approval. The CEO of PMI has said that the results are encouraging. However, scepticism remains over the research methodology with some scientists claiming that it is skewed and biased.
“Cigarette shipping volume remains poor in the second quarter with the largest declines occurring within Eastern Europe, Latin America and Canada. This is partially offset by volume increases in North Africa and South East Asia, but overall worldwide shipping volume has declined. This is likely to continue in the future as PMI continues to pursue value with their Heated Tobacco products and steer away cigarettes and other smoking products.”
ENDS
For more information
To gain access to our latest press releases: GlobalData Media Centre
Analysts available for comment. Please contact the GlobalData Press Office:
EMEA & Americas: +44 (0)207 832 4399
Asia-Pacific: +91 40 6616 6809
GlobalData.com | LinkedIn | Twitter
About GlobalData
4,000 of the world’s largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s unique data, expert analysis and innovative solutions, all in one platform. GlobalData’s mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors. |
|
|
|
Delta 9 Enters Licensing Agreement with Nanosphere Health Sciences
/NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES/
WINNIPEG, July 31, 2018 /CNW/ - DELTA 9 CANNABIS INC. (TSXV: NINE) ("Delta 9" or the "Company") is pleased to announce it has signed memorandum of understanding (the "MOU") with Nanosphere Health Sciences Inc. (CSE: NSHS) ("Nanosphere"). The MOU provides that Delta 9 and Nanosphere intend to negotiate and enter into a master agreement (the "Agreement") pursuant to which Nanosphere will grant a master license for Nanosphere's patented technology to Delta 9 for all of Canada. Delta 9 may also sub-license the technology to other licensed producers of cannabis under the Access to Cannabis for Medical Purposes Regulations (the "ACMPR").
Nanosphere is a nano-biotechnology company focused on providing next generation delivery of nutritional elements and medications. The company's patented NanoSphere Delivery System™ platform technology addresses the problems of low bioavailability and excessive dosage amounts of a wide range of bioactive compounds, including cannabinoids.
The NanoSphere Delivery System™ provides more bioavailability in comparison to other methods of delivery by transporting essential ingredients directly to the bloodstream and cells. Nanosphere's cannabis brand, Evolve Formulas, currently has products on sale in over 200 dispensaries across Colorado and has signed licensing agreements to bring products to California and Arizona in the coming months. It also holds the patent for delivery of cannabis via phospholipid nanoparticles, as well as a master patent covering its core technology.
"We are very excited to reach this agreement with Nanosphere," said Delta 9 CEO John Arbuthnot. "We believe Nanosphere has developed on of the world's most advanced delivery system for cannabinoids. We believe this partnership will revolutionize the medical use of cannabis in Canada and around the world, and that it also has important applications in the recreational market."
Nanosphere has developed a delivery system that shrinks active drug ingredients and encapsulates them in phospholipid nanoparticles, allowing the agents, including cannabis, to pass through skin or mucous membrane and go straight into the bloodstream. This process allows for a significant increase in the bioavailability of the drug, and also allows for extremely precise dosage of any drug, including cannabis. Nanosphere products can be applied as a transdermal viscous gel that absorbs into the skin; as an intranasal product for fast-acting effects; or as an intraoral product which is absorbed through the mucous membrane into the bloodstream.
Robert Sutton, Chairman and CEO of Nanosphere, says the agreement marks a great stride forward for his company. "With this agreement we have a trusted and experienced partner in the only G7 nation that has legalized cannabis for both medical and recreational use," Sutton said. "This allows Nanosphere's technology to be subjected to clinical trials and to be appropriately distributed to both patients and to recreational users of cannabis. We hope through our work to eliminate the need for patients to be essentially "smoking their medicine", and to give physicians a new and important tool to treat conditions that respond to cannabinoids."
The MOU provides that Delta 9 and Nanosphere will each receive 50 per cent of the net revenue from sales of Nanosphere products in Canada if the Agreement is entered into. Delta 9 will have the right to sub-contract distribution to third-party license holders in Canada where the opportunity exists. Under those circumstances, Delta 9 would receive a portion of that sub-licensee's net profit, and remit 50 per cent of the net revenue to Nanosphere.
The initial term of the Agreement is intended to be 36 months following the date of the first commercial sale of licensed products pursuant to the Agreement. The Agreement is intended to be renewed by mutual agreement of the parties. Also, if the Agreement is entered into, Delta 9 is bound to apply to Health Canada for authorization to distribute Nanosphere products. The parties intend that the MOU will be replaced by the Agreement within 60 days, upon completion of due diligence by both parties.
About Delta 9 Cannabis Inc.
Delta 9's wholly-owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical marijuana pursuant to the ACMPR and operates an 80,000 square foot production facility in Winnipeg, Manitoba, Canada. Delta 9's shares trade on the TSX Venture Exchange under the symbol "NINE".
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Disclaimer for Forward-Looking Information
Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the Company's future business plans and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to: (i) the entering into of the Agreement, the terms of the Agreement and the granting of the license for Nanosphere's products to Delta 9; (ii) the development of Nanosphere's products; and (iii) sublicensing of Nanosphere's products by Delta 9. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including that Delta 9's currently contemplated expansion and development plans may cease or otherwise change, Delta 9's production of cannabis may be lower than expected, Delta 9 may not obtain the required approvals from Health Canada, demand for Delta 9's products may be lower than anticipated, Delta 9's cost to produce its grow pods may be higher than expected and all other risk factors set forth in the annual information form of Delta 9 dated May 31, 2018 which has been filed on SEDAR. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.
SOURCE Delta 9 Cannabis Inc.
